Gastroenterology
Volume 135, Issue 5 , Pages 1561-1567 , November 2008

Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

  • Peter Ferenci

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • Corresponding Author InformationAddress requests for reprints to: Peter Ferenci, MD, Prof, Universitätsklinik für Innere Medizin III, Medical University of Vienna, AKH, Waehringer Guertel 18-20, A 1090 Wien, Austria. fax: (43) 1 0 40400 4735
    • ,
  • Thomas–Matthias Scherzer

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Heidrun Kerschner

      Affiliations

    • Clinical Institute of Virology, Medical University of Vienna, Austria
    • ,
  • Karoline Rutter

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Sandra Beinhardt

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Harald Hofer

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Maximilian Schöniger–Hekele

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Heidemarie Holzmann

      Affiliations

    • Clinical Institute of Virology, Medical University of Vienna, Austria
    • ,
  • Petra Steindl–Munda

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria

Received 28 May 2008 ,Accepted 24 July 2008.

References 

  1. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod. 2003;66:1171–1174
  2. Pietrangelo A, Borella F, Casalgrandi G, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology. 1995;109:1941–1949
  3. Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of Silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis (Results of a randomized, double-blind, placebo-controlled clinical study). Int J Clin Pharmacol Ther. 2002;40:2–8
  4. Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol. 1994;48:753–759
  5. Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced bilary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1987;26:643–649
  6. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749–754
  7. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of Silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105–113
  8. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol. 2007;5:408–416
  9. Hruby K, Csomos G, Fuhrmann M, et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol. 1983;2:138–195
  10. Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res. 1986;213:319–331
  11. Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res. 2006;34:65–73
  12. Waris G, Turkson J, Hassanein T, et al. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol. 2005;79:1569–1580
  13. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366–375
  14. Janssen YM, Matalon S, Mossman BT. Differential induction of c-fos, c-jun, and apoptosis in lung epithelial cells exposed to ROS or RNS. Am J Physiol. 1997;273:789–796
  15. Di Bona D, Cippitelli M, Fionda C, et al. Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol. 2006;45:271–279
  16. Cesarone M, Belcaro G, Carratelli M, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18:127–130
  17. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132:1925–1936
  18. Varghese L, Agarwal C, Tyagi A, et al. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005;11:8441–8448
  19. Tanamly MD, Tadros F, Labeeb S, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36:752–759
  20. Gabbay E, Zigmond E, Pappo O, et al. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol. 2007;13:5317–5323
  21. Zhang L, Zuo Z, Lin G. Intestinal and hepatic glucuronidation of flavonoids. Mol Pharmaceutics. 2007;4:833–845
  22. Gordon A, Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:275–280
  23. Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profile of free, conjugated and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008;36:65–72
  24. Schrieber SJ, Wen Z, Dumas TE, et al. Silymarin pharmacokinetics (PK) is altered in patients with chronic hepatitis C (HCV) and nonalcoholic fatty liver disease (NAFLD) and correlates with caspase 3/7 activity. Hepatology. 2007;46(Suppl 1):A-392
  25. Lee J, Wu CC, Lee KJ, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A. 2006;103:1828–1833
  26. Grandvaux N, Gaboriau F, Harris J, et al. Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response. FEBS J. 2005;272:3120–3131
  27. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther. 2003;98:129–142
  28. Nahmias Y, Goldwasser J, Casali M, et al. Apolipoprotein B-dependent hepatitis c virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008;47:1437–1445
  29. Sabile A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology. 1999;30:1064–1076

 Trial registered at: www.clinicaltrials.gov: NCT00684268.

 The authors disclose the following: Conflicts of interest: P. Ferenci: Roche, Basel, CH; member of the Global Advisory Board and of the speakers bureau and receives financial support for clinical studies. All other authors have no conflicts of interest.

 Supported by an unrestricted research grant by Roche Austria, and silibinin (Legalon Sil) and silimaryin (Legalon) were provided by Rottapharm-Madaus, Köln, Germany. None of the companies was involved in the design, conduct, and evaluation of this protocol.

PII: S0016-5085(08)01412-1

doi: 10.1053/j.gastro.2008.07.072

Gastroenterology
Volume 135, Issue 5 , Pages 1561-1567 , November 2008

Article Tools

* Image Usage & Resolution